On Tuesday, Delix Therapeutics announced positive topline data from a small Phase Ib study of DLX-001 in major depressive disorder (MDD). DLX-001, also known as zalsupindole, is an analog of 5-MeO-DMT that the company describes as a non-hallucinogenic neuroplastogen. 18 patients were dosed with DLX-001, either once daily for seven days or twice during the seven-day period.
